Monoclonal antibodies in cancer therapy

Oldham, R.K. (1983). Monoclonal antibodies in cancer therapy. J. Clin. Oncol. 1 582-590. 

Stem M, Herrmann R. 2005. Overview of monoclonal antibodies in cancer therapy Present and promise. Crit Rev Oncol Hematol. 54 11-29. 

Bivalent and Bispecific Monoclonal Antibodies in Cancer Therapy... 

Fig. 3.4 Modes of action of monoclonal antibodies in cancer therapy. scFv single-chain Fv fragment. (Reproduced from Carter, P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer1 118-129).

Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy 25 years of progress. Journal of Clinical Oncology 2008 26 1774-1777. 

Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007 12 1084-1095. 

M. Driscoll, R. Hcuisen, C. Ding, D.E. Cramer, J. Yan, Therapeutic potential of various P-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biology Therapy, 8 (3), 216-223, 2009. 

Scott, A.M., Allison, J.P., Wolchok, J.D., 2012. Monoclonal antibodies in cancer therapy. Cancer Immun. 

In addition to the three main types of immunological products that are widely available, more specialized preparations include synthetic peptide immune response modifiers such as those used to block T-cell responses in multiple sclerosis labelled monoclonal antibodies for cancer therapy or diagnosis and hybrid toxins containing a bacterial or plant toxin subunit attached to an antibody or human cell receptor-binding protein, and also intended mainly for cancer therapy. These have rather limited applications and for the most part, are designed to suppress or exploit the specificity of immune responses rather than to stimulate them. 

Sell, S., Cancer Marker, Past, present and future. In Monoclonal Antibodies and Cancer Therapy. R.A. Reisfeld (Ed.), Alan R. liss. New York, 1985. 

Yang X-D et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Critical Reviews in Oncology Hematology 2001 38 17-23. 

Thorpe, P. E. (1985) Antibody carriers of cytotoxic agents in cancer therapy a review, in Monoclonal Antibodies 84 Biological and Clinical Applications (Pinchera, A., Doria, G., Dammacco, F., and Bargellesi, E., eds.), Editrice Kurds s. r. 1., Milan, pp. 475-506. 

Okamoto OK, Perez JF. Targeting cancer stem cells with monoclonal antibodies A new perspective in cancer therapy and diagnosis. Expert Rev Mol Diagn 2008 8 387-393. 

Besides being used for site-specific delivery of chemotherapeutic drugs, peptides, proteins, or radionuclides in cancer therapy, monoclonal antibodies have... 

Goldberg RM. Lessons learned from the edrecolomab story how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Onkologie 2005 28(6-7) 311-2. 

Over the past decade, a wide variety of antibody-based targeting molecules have been assessed for their potential application in cancer therapy [200]. Monoclonal antibodies (mAb) were the first and are still the preferred class of targeting molecules. Current developments of antibodies have been focused on chimeric, humanized, and fully humanized derivatives to decrease their immunogenicity. Some of these antibody-based drugs have already undergone clinical development and have been successfully translated into the clinical environment. Such examples include rituximab (Rituxan ), trastuzumab (Herceptin ), cetuximab (Erbitux ), and bevacizumab (Avastin ). Rituximab was approved by the FDA for treating B-cell lymphoma in 1997. 

---